Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.nejm.org › doi › fullEffect of Early Treatment with Ivermectin among Patients with...

   www.nejm.org › doi › full

   30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...

   • Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others

     Alopecia areata is an autoimmune condition characterized by...

   • Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith

     A 53-year-old landscaper presented with a 4-month history of...

   • Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay

     Notwithstanding ongoing confusion over the concepts of...

   • Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes

     Nonspecific low back pain is diagnosed by ruling out other...

   • Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries

     Scalp hair regrowth is associated with improvements in...

   • Clinical Problem-Solving Looking Back L. Glick and Others

     The creatinine level was 2.6 mg per deciliter (230 μmol per...

2. www.nejm.org › doi › fullIvermectin Treatment for Covid-19 | NEJM - New England Journal of...

   www.nejm.org › doi › full

   14 gru 2022 · Given the wide availability and low cost of ivermectin and that the dosage used in the trial appeared to be safe, such treatment effects could be an important benefit for high-risk patients...

3. pmc.ncbi.nlm.nih.gov › articles › PMC9308124Systematic review and meta-analysis of ivermectin for treatment...

   pmc.ncbi.nlm.nih.gov › articles › PMC9308124

   Ravikirti, Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, Manjhi PK, et al. Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in Eastern India.

4. pubmed.ncbi.nlm.nih.gov › 34265236Evaluation of Ivermectin as a Potential Treatment for Mild to...

   pubmed.ncbi.nlm.nih.gov › 34265236

   Methods: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1st August and 31st October 2020.

5. india.cochrane.org › evidenceIs ivermectin effective for COVID-19? | Cochrane India

   india.cochrane.org › evidence

   • Zapisane w pamięci cache

   We evaluated the effects of ivermectin in infected people on: people dying; whether people's COVID-19 symptoms got better or worse; unwanted effects; hospital admission or time in hospital; viral clearance. For prevention, we sought the effect on preventing COVID-19 and SARS-CoV-2 infection.

6. pubmed.ncbi.nlm.nih.gov › 33592050Role of ivermectin in the prevention of SARS-CoV-2 infection...

   pubmed.ncbi.nlm.nih.gov › 33592050

   16 lut 2021 · Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Chemoprophylaxis has relevance in the containment of pandemic.

7. www.ncbi.nlm.nih.gov › pmc › articlesIvermectin as a multifaceted drug in COVID-19: Current insights

   www.ncbi.nlm.nih.gov › pmc › articles

   26 lip 2021 · In this study, single addition of 5 μM Ivermectin to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 demonstrated ∼5000-fold reduction in viral RNA at 48 h. 7 The anti-viral mechanism of Ivermectin in COVID-19 is attributed to inhibition of the importin (IMP) α/β receptor, which is responsible for transmitting viral proteins into the ...